-
Longitudinal Course of Adverse Events With Esketamine Nasal Spray: A Post Hoc Analysis of Pooled Data From Phase 3 Trials in Patients With Treatment-Resistant Depression.
Williamson, David J; Gogate, Jagadish P; Kern Sliwa, Jennifer K; Manera, Lewis S; Preskorn, Sheldon H; Winokur, Andrew; Starr, H Lynn; Daly, Ella J The Journal of Clinical Psychiatry. 2022 Sep 19; 21m14318.doi:10.4088/JCP.21m14318. PMID: 36149841 2022 Sep;83(6):
-
Subanalysis of the CYP-GUIDES Trial: CYP2D6 Functional Stratification and Operational Timeline Selection.
Ruaño G, Tortora J, Robinson S, Baker S, Holford T, Winokur A, Goethe JW Psychiatry Res 297 (2021)113571 2021 Mar;297113571
-
Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial.
Publication 2019
Daly, Ej, Trivedi, MH, Janik, A,Zhang, Y, Lane, R, Lim, P, Duca, AR, Hough, D, Thase, ME Zajecki, Winokur, A, Divacka, I, Fagiolini, A, Cubala, WJ, Bitter, I, Shelton RC, Molero, P, Manji, H, Drevets, WC, Singh JB. Efficacy of esketamine nasal spray plus oral antidpressant treatment for relapse prevention in patients with treatment-resistant depression. JAMA Psychiatry 2019; 76(9), 893-903, 2019 JAMA psychiatry 2019 Jun;
-
Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial.
Daly, Ella J; Singh, Jaskaran B; Fedgchin, Maggie; Cooper, Kimberly; Lim, Pilar; Shelton, Richard C; Thase, Michael E; Winokur, Andrew; Van Nueten, Luc; Manji, Husseini; Drevets, Wayne C JAMA psychiatry 2017 Dec;75139-148
-
Sleep Patterns and Neuropsychiatric Symptoms in Hospitalized Patients With Dementia.
Tanev, Kaloyan S; Winokur, Andrew; Pitman, Roger K The Journal of neuropsychiatry and clinical neurosciences 2017 Mar;29248-253
-
A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression.
Singh, Jaskaran B; Fedgchin, Maggie; Daly, Ella J; De Boer, Peter; Cooper, Kimberly; Lim, Pilar; Pinter, Christine; Murrough, James W; Sanacora, Gerard; Shelton, Richard C; Kurian, Benji; Winokur, Andrew; Fava, Maurizio; Manji, Husseini; Drevets, Wayne C; Van Nueten, Luc The American journal of psychiatry 2016 Apr;173816-26
-
Thyrotropin-releasing hormone as a treatment for cancer-related fatigue: a randomized controlled study.
Kamath, Jayesh; Feinn, Richard; Winokur, Andrew Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2012 Aug;20(8):1745-53
-
Thyrotropin-releasing hormone can relieve cancer-related fatigue: hypothesis and preliminary observations.
Kamath, J; Yarbrough, G G; Prange, A J; Winokur, A The Journal of international medical research 2009 Jan;37(4):1152-7
-
Thyrotropin-releasing hormone (TRH) in the neuroaxis: therapeutic effects reflect physiological functions and molecular actions.
Yarbrough, G G; Kamath, J; Winokur, A; Prange, A J Medical hypotheses 2007 Jan;69(6):1249-56
-
Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression.
Kramer, Mark S; Winokur, Andrew; Kelsey, Jeffrey; Preskorn, Sheldon H; Rothschild, Anthony J; Snavely, Duane; Ghosh, Kalyan; Ball, William A; Reines, Scott A; Munjack, Dennis; Apter, Jeffrey T; Cunningham, Lynn; Kling, Mitchel; Bari, Mohammed; Getson, Albert; Lee, Yih Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2004 Feb;29(2):385-92
-
Depression, sleep physiology, and antidepressant drugs.
Winokur, A; Gary, K A; Rodner, S; Rae-Red, C; Fernando, A T; Szuba, M P Depression and anxiety 2001 Jan;14(1):19-28
-
Lack of correlation between cerebrospinal fluid thyrotropin-releasing hormone (TRH) and TRH-stimulated thyroid-stimulating hormone in patients with depression.
Frye, M A; Dunn, R T; Gary, K A; Kimbrell, T A; Callahan, A M; Luckenbaugh, D A; Corá-Locatelli, G; Vanderham, E; Winokur, A; Post, R M Biological psychiatry 1999 Apr;45(8):1049-52
-
Opening the Doors of Prescription: Historical Contexts and Current Clinical Perspectives on Psychedelics in Psychiatry
Connecticut Medicine, 86(1):61-71, 2022
